GlassScriptPhysician profile
Clarissa Geyer
NPI 1528264223
$9,083.70
in general payments reported to CMS, 2019-2025
59 companies · $2,366 in 2025
The $2,366 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,181 · 2020: $455 · 2021: $719 · 2022: $927 · 2023: $1,466 · 2024: $1,971 · 2025: $2,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,757 · Education: $45.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,756.70 |
| Education | $45.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $721.02 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $674.28 | 2019-2025 | Tagrisso, Calquence, Enhertu |
| Genentech USA, INC. | $650.47 | 2019-2025 | Polivy, Itovebi, Venclexta |
| Celgene Corporation | $627.58 | 2019-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $547.72 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $492.50 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $396.15 | 2019-2025 | |
| Amgen INC. | $376.63 | 2019-2023 | Lumakras |
| Genzyme Corporation | $359.96 | 2019-2025 | |
| Incyte Corporation | $331.91 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Eisai INC. | $312.37 | 2019-2025 | |
| Lilly USA, LLC | $243.31 | 2020-2025 | Jaypirca, Verzenio, Retevmo |
| Astellas Pharma US INC | $237.42 | 2019-2025 | Vyloy, Padcev, Xospata |
| Seagen INC. | $221.64 | 2019-2023 | Tukysa, Padcev |
| Janssen Biotech, INC. | $221.58 | 2019-2025 | Rybrevant, Darzalex, Imbruvica |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $214.81 | 2019-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $159.27 | 2019-2024 | Ninlaro, Fruzaqla |
| Daiichi Sankyo INC. | $146.70 | 2019-2025 | Enhertu |
| Rigel Pharmaceuticals, INC. | $133.56 | 2022-2024 | Rezlidhia, Tavalisse |
| Boston Scientific Corporation | $131.69 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Glaxosmithkline, LLC. | $129.67 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.90 | 2019-2024 | Gilotrif |
| Abbvie INC. | $99.89 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $99.69 | 2019-2025 | Onivyde |
| Pharmacosmos Therapeutics INC. | $93.96 | 2025 | Monoferric |
| Tersera Therapeutics LLC | $83.18 | 2022-2024 | Zoladex, Xermelo |
| Pharmacyclics LLC, An Abbvie Company | $83.02 | 2021-2023 | Imbruvica |
| Regeneron Healthcare Solutions, INC. | $76.16 | 2019-2024 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $68.73 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $65.12 | 2022-2025 | |
| Beone Medicines USA, INC. | $62.81 | 2025 | Brukinsa |
| Kyowa Kirin, INC. | $61.00 | 2019-2025 | Poteligeo |
| Amag Pharmaceuticals, INC. | $59.29 | 2019-2021 | |
| Beigene USA, INC. | $59.04 | 2021-2024 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $54.14 | 2019-2023 | Ultomiris |
| Tempus Ai, INC | $53.78 | 2024 | Xt Cdx |
| Taiho Oncology, INC. | $50.96 | 2019-2025 | |
| Novocure INC. | $47.25 | 2024 | Optune Lua (Novottf-200t) |
| Sobi, INC | $45.87 | 2022-2023 | |
| Puma Biotechnology, INC. | $45.62 | 2019-2025 | |
| Gilead Sciences, INC. | $45.20 | 2022-2025 | Trodelvy |
| Array Biopharma INC | $44.04 | 2022-2025 | Lorbrena, Braftovi |
| Emd Serono, INC. | $32.65 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $29.37 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $25.72 | 2025 | |
| Blue Earth Diagnostics | $23.78 | 2022 | |
| Jazz Pharmaceuticals INC. | $23.76 | 2025 | |
| Geron Corporation | $22.92 | 2025 | Rytelo |
| Azurity Pharmaceuticals, INC. | $22.87 | 2025 | Vivimusta, Danziten |
| Caris Mpi, INC. | $20.44 | 2025 | Mi Cancer Seek |
| Coherus Oncology, INC. | $19.20 | 2020 | |
| Legend Biotech USA INC. | $18.65 | 2025 | Carvykti |
| Karyopharm Therapeutics INC. | $17.80 | 2023 | Xpovio |
| Pharmaessentia USA Corporation | $17.67 | 2022 | |
| Mylan Institutional INC. | $17.58 | 2019 | |
| Dova Pharmaceuticals | $16.14 | 2019 | |
| Verastem, INC. | $15.04 | 2019 | |
| Morphosys, US INC. | $14.20 | 2023 | Monjuvi |
| Aadi Bioscience, INC. | $14.02 | 2023 | Fyarro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clarissa Geyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.